ALLO Stock Price History and Quote Analysis Insights for Investors

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ALLO shares is 227, representing 80.25% of the company's common stock.

EXODUSPOINT CAPITAL MANAGEMENT, LP, in the last quarter, reduced its stake in ALLO by -64.78% restricting it's holding to 163.02 thousand shares of worth nearly $729.00K. AMERIPRISE FINANCIAL INC also lessened -0.66% of the ALLO shares from its portfolio, reducing its holding to 189.04 thousand shares of worth $845.01K. GOLDMAN SACHS GROUP INC also shunned ALLO shares holding by -61.21% last quarter which brought its holding to 1.29 million shares worth $5.79M.

As per its latest 13F filing, UBS ASSET MANAGEMENT AMERICAS INC increased its stake in ALLO by 8.66% in the last quarter. The institutional holder raised its holding to 170.29 thousand shares having worth more than $761.18K. PDT PARTNERS, LLC also added 1,085.57% more shares of ALLO to its portfolio, raising its holding to 189.03 thousand shares of worth $844.96K. D. E. SHAW & CO., INC. also increased its ALLO shares holding by 158.83% which brought its holding to 195.78 thousand shares worth $875.13K.

The insider with the most stakes in ALLO is N/A , N/A at the company. Additionally, ALLO stock is highly held by N/A N/A and N/A N/A among others.

Company executives, directors, and other insiders own 17.43% percent of Allogene Therapeutics, Inc.'s stock. Within the last six months, there have been 2 transaction(s) in which ALLO insiders have sold stock, totaling 18.36K shares. Insiders that have sold shares include MESSEMER DEBORAH M., HUMER FRANZ B, and MAYO STEPHEN.

There have been 0 transaction(s) during the past 6-months in which Allogene Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 465.14K Allogene Therapeutics, Inc. shares are held by insiders, which represents about 17.43% of ALLO stock.

ALLO N/A, N/A holds the largest portfolio of the company's shares. ALLO shares owned by N/A total nearly -.

EXODUSPOINT CAPITAL MANAGEMENT, LP is the largest institutional owner in ALLO which holds 163.02 thousand shares worth $729.00K or 0.1% of the total ALLO shares outstanding followed by UBS ASSET MANAGEMENT AMERICAS INC with ownership of 170.29 thousand shares representing 0.1% of the ALLO ownership. PDT PARTNERS, LLC is the third largest stakeholder with 189.03 thousand shares or 0.11% of the ownership worth more than $844.96K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ALLO is concerned, it is a stock which is optionable.

Number of ALLO shares short is 39.32M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 209.67M shares of ALLO are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ALLO has 151.87M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ALLO is 19.93.